BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.

Nov 21, 2024 · Drug development is an expensive, risky endeavor. Biotechnology companies just starting out are many years away from seeing profits, if ever. So more often than not, a startup’s success turning science into medicines can come down to how much money it raises.

Dec 11, 2024 · An experimental breast cancer drug developed by Eli Lilly met its main goal in a Phase 3 study, helping people with a form of HER2-negative, ER-positive disease stay alive and progression free for longer than standard hormone-suppressing therapies, according to data disclosed Wednesday.. When combined with Lilly’s approved medicine Verezenio, the experimental drug, called imlunestrant, also ...

Dec 17, 2024 · Dive Insight: Pfizer hopes 2025 is the year its revenue becomes predictable again. The company soared to new heights during the pandemic as its COVID vaccine and Paxlovid became mainstay treatments and earned it tens of billions of dollars.

Oct 9, 2024 · AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines The startup, which is building a database of biological interactions found in nature, also secured $60 million in funding from a group of life sciences and tech investors.

May 8, 2024 · Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay for many years, even decades, and allows pharmaceutical companies to set higher prices than they otherwise could.

Oct 28, 2024 · AbbVie has agreed to acquire a young company with drugmaking technology from Johnson & Johnson and an experimental treatment for Alzheimer’s disease that’s in the first stage of human testing.. The deal, announced Monday, is expected to close by the end of the year, and has AbbVie buying all the outstanding shares of Aliada Therapeutics for $1.4 billion in cash.

Jan 16, 2024 · Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024.. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a more strident Federal Trade Commission, further weighed on the sector.. There are now some signs of a turnaround, from a rebounding ...

Oct 10, 2024 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.

Jan 24, 2025 · The latest biotech news for biopharmaceutical professionals. Intellia makes progress on HAE study; 2 more China drug deals The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment.